ZBIO Zenas BioPharma, Inc.

Nasdaq zenasbio.com


$ 29.74 $ 1.87 (6.68 %)    

Thursday, 30-Oct-2025 19:40:12 EDT
QQQ $ 633.20 nm (nm)
DIA $ 475.83 $ -1.36 (-0.29 %)
SPY $ 684.43 nm (nm)
TLT $ 90.42 nm (nm)
GLD $ 371.67 $ 7.13 (1.96 %)
$ 29.88
$ 27.53
$ 29.74 x 5
$ 32.00 x 100
-- - --
$ 5.83 - $ 34.33
393,995
na
1.25B
$ 0.77
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-12-2025 06-30-2025 10-Q
2 05-15-2025 03-31-2025 10-Q
3 03-11-2025 12-31-2024 10-K
4 11-12-2024 09-30-2024 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

Citigroup analyst Yigal Nochomovitz maintains Zenas BioPharma (NASDAQ:ZBIO) with a Buy and raises the price target from $27 ...

Core News & Articles

Morgan Stanley analyst Vikram Purohit maintains Zenas BioPharma (NASDAQ:ZBIO) with a Overweight and raises the price target ...

Core News & Articles

HC Wainwright & Co. analyst Matthew Caufield maintains Zenas BioPharma (NASDAQ:ZBIO) with a Buy and raises the price tar...

Core News & Articles

- SEC Filing

Core News & Articles

Wedbush analyst Martin Fan maintains Zenas BioPharma (NASDAQ:ZBIO) with a Outperform and raises the price target from $35 t...

Core News & Articles

HC Wainwright & Co. analyst Matthew Caufield reiterates Zenas BioPharma (NASDAQ:ZBIO) with a Buy and maintains $30 price...

Core News & Articles

We may offer and sell from time to time, in one or more series or issuances and in an amount and on terms that we will determin...

 zenas-biopharma-raises-120-million-to-secure-global-rights-to-multiple-sclerosis-drug

Zenas BioPharma secures global rights to orelabrutinib in multiple sclerosis, expands autoimmune pipeline, and raises $120 mill...

Core News & Articles

Zenas BioPharma, Inc. ("Zenas," "Zenas BioPharma" or the "Company") (NASDAQ:ZBIO) and InnoCare Pharma L...

Core News & Articles

Zenas BioPharma (NASDAQ:ZBIO) reported quarterly losses of $(1.25) per share which missed the analyst consensus estimate of $(1...

Core News & Articles

HC Wainwright & Co. analyst Matthew Caufield reiterates Zenas BioPharma (NASDAQ:ZBIO) with a Buy and maintains $30 price...

Core News & Articles

Zenas BioPharma (NASDAQ:ZBIO) reported quarterly losses of $(0.80) per share which beat the analyst consensus estimate of $(1.0...

 zenas-biopharma-gains-outperform-rating-from-analyst-as-key-autoimmune-trials-progress

Wedbush initiates coverage on Zenas BioPharma, citing strong potential for obexelimab in autoimmune diseases, with key clinical...

Core News & Articles

Wedbush analyst Martin Fan initiates coverage on Zenas BioPharma (NASDAQ:ZBIO) with a Outperform rating.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION